Sanofi Pasteur and KaloBios Pharmaceuticals have announced the issuance of FDA fast track designation for novel biologic candidate KB001A targetting Pseudomonas Aeruginosa (Pa). An antibody fragment KB001A is developed against Pa that ...
Tags: Sanofi Pasteur, KB001A